-- GSK3036656 demonstrated early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis
-- Treatment was generally well tolerated with no serious adverse events identified
-- Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future
-- TB remains leading global cause of death from infectious disease and new treatments are urgently needed

• New investment supports further innovation in malaria, tuberculosis, and HIV, with a new emphasis on Neglected Tropical Diseases and anti-microbial resistance
• GSK Global Health R&D Hubs are progressing more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases
• GSK will also maintain donations of albendazole until the elimination of lymphatic filariasis, and double production of its adjuvant for use in the RTS,S malaria vaccine
• New commitments support GSK’s ambition to positively impact the health of more than 2.5 billion people in the next ten years

23 June 2022, London UK: GSK plc (LSE/NYSE: GSK) announced today an investment of £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries.

-- A new global collaboration of philanthropic, non-profit and private sector organizations will work together to accelerate the development of novel TB treatment regimens for all TB patients.
-- The global collaboration aims to create treatment regimens comprised of medicines to which there is limited or no drug resistance and that are ready for phase 3 development.
-- The regimens could be an important step toward addressing the current global challenges around TB treatment complexity, and the diagnosis and treatment of drug-resistant TB.

-- The M72/AS01E tuberculosis vaccine candidate demonstrated in a phase IIb trial the potential to reduce active pulmonary TB by half in adults with latent TB infection.[1]
-- Developing a new vaccine against TB is a global health priority to accelerate progress toward ending the TB epidemic[2] and one of the United Nations Sustainable Development Goals
-- The licensing agreement is a significant step forward to continue the development of the vaccine candidate for low-income countries with high TB burdens.

-- Final analysis of phase IIb study published today in the New England Journal of Medicine and presented at the 50th Union World Conference on Lung Health.

-- Final results confirm the innovative TB candidate vaccine’s efficacy level and acceptable safety profile in three-year clinical trial conducted in sub-Saharan African regions.

Publication of primary results in the New England Journal of Medicine shows positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions.

UNIVERSITY PARK, Pa., June 27, 2016 -- A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).